Pfizer will pay $1.25 billion upfront to license an experimental cancer drug out of China, in a deal that underscores ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Merck Animal Health is investing $895 million in a De Soto new facility, which will bring hundreds of jobs. It’s a huge economic investment for the company, and the small town.

Researchers analyzed long-term survival of women diagnosed with low-risk cervical cancer, from 2010 through 2017, who ...

Trump's tariffs are meant to promote investment in domestic manufacturing, but experts told Scripps News the reality of ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the ...

S&P 500 pharma stocks hold firm despite Trump’s drug pricing threat. Is Merck a put-selling opportunity amid headline noise?

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...

We believe that Merck KGaA enjoys a narrow moat, driven by intangible assets and switching costs which are prevalent in its Life Science and Electronics businesses. A few acquisitions to fill gaps in ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...